Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
You may also be interested in...
China Leadership Changes Signal MSD-Simcere JV Shakeup
With the two top execs at MSD-Simcere jumping ship, there was speculation that the JV could be in trouble, but MSD reiterates its strong commitment to China and the JV as the company hastens its pace in the country to introduce more products.
Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?
Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?